{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-008679","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.447880+00:00","generated_at":"2026-06-26T11:01:39.332166+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anebulo doses >50% of subjects in Phase 2 trial for acute cannabinoid intoxication; expects IND by end of 2022","bullets":["Dosed more than half of the 60 planned subjects in Part A of Phase 2 trial for ANEB-001 at CHDR in Netherlands.","Top-line data for Part A expected by end of H1 2022.","Plan to include Part A data in IND submission to FDA; expects to file IND before end of 2022.","CEO Simon Allen states robust enrollment enables smoother bridge to U.S. trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-008679","json":"https://secwatch.observer/filing/0001493152-22-008679.json","markdown":"https://secwatch.observer/filing/0001493152-22-008679.md","text":"https://secwatch.observer/filing/0001493152-22-008679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222008679/0001493152-22-008679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222008679/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T11:01:39.332166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}